Francesco Bibbiani

Francesco brings more than two decades of experience in development, including a focus on rare neuromuscular diseases as well as Duchenne muscular dystrophy (DMD). He joins Dyne from Ultragenyx Pharmaceutical Inc., where he served as vice president of global clinical development and oversaw all stages of the development of neuromuscular and neurology product candidates, providing strategic direction and technical leadership to the clinical development team, including for the company’s gene therapy program in DMD. While at Ultragenyx, he was also a member of the DMD Gene Therapy Working Group, comprised of leading experts from the industry and academia collaborating to optimize and provide guidelines for gene therapy in DMD. Previously, Dr. Bibbiani was the vice president of clinical development for PTC Therapeutics, Inc., overseeing multiple clinical trials in DMD and lifecycle management for all products in its neuromuscular portfolio. Prior to PTC Therapeutics, he held several roles at Eisai, Inc. as a project and clinical lead, overseeing global clinical development plans and leading multiple New Drug Applications. He received his M.D. and board certification in neurology from the University of Pisa, Italy. Following that, he completed his fellowship at the National Institutes of Health in Experimental Therapeutics.